Search

Your search keyword '"Mourad, J. J."' showing total 351 results
Start Over Author "Mourad, J. J."
351 results on '"Mourad, J. J."'

5. Benefit of treatment based on indapamide mostly combined with perindopril on mortality and cardiovascular outcomes: a pooled analysis of four trials

Author

Chalmers, J, Mourad, J, Brzozowska-Villatte, R, De Champvallins, M, Mancia, G, Chalmers J., Mourad J. -J., Brzozowska-Villatte R., De Champvallins M., Mancia G., Chalmers, J, Mourad, J, Brzozowska-Villatte, R, De Champvallins, M, Mancia, G, Chalmers J., Mourad J. -J., Brzozowska-Villatte R., De Champvallins M., and Mancia G.

Abstract

Objective:The aim of this study was to assess the reduction in all-cause death and cardiovascular outcomes associated with the administration of the thiazide-like diuretic indapamide monotherapy or in combination with perindopril as a blood pressure lowering drug in randomized controlled trials (RCTs).Method:Aggregate data from four published RCTs conducted versus matching placebo were pooled: PATS, a 2-year study (indapamide), and PROGRESS, a 4-year study (indapamide and perindopril), both in patients with a history of stroke or transient ischemic attack; ADVANCE, a 4-year study in patients with type 2 diabetes and cardiovascular risk factor (single-pill combination perindopril/indapamide) and HYVET, a 2-year study in very elderly hypertensive individuals (indapamide and an option of perindopril). The pooled effect (fixed and random) estimate (hazard ratio) was reported with corresponding 95% confidence intervals and P values. Treatment discontinuations were also analysed to assess the net benefit of the treatment.Results:The population involved 24 194 patients (active: 12 113, placebo: 12 081). The fixed-effects meta-analysis of the three mortality endpoints found low statistical heterogeneity (I2= 0). Statistically significant risk reductions in the indapamide with or without perindopril-treated patients as compared to placebo were observed for all-cause death (-15%), cardiovascular death (-21%), fatal stroke (-36%) and all strokes (-27%). Other cardiovascular outcomes were improved (risk reduction, 22 to 36%). As expected, discontinuation rates for safety (two studies) were higher in the active group (6.4 vs. 3.9%), while they were similar when discontinuation for any reason is concerned (18.4 vs. 18.0%).Conclusion:Across medium to high cardiovascular risk population, long-term indapamide, mostly combined with perindopril-based treatment, provided evidence of benefit on mortality and morbidity.

Published
2023

9. Recommandation : Prise en charge de l’hypertension artérielle de l’adulte

Author

Blacher, J., Halimi, J.-M., Hanon, O., Mourad, J.-J., Pathak, A., Schnebert, B., Girerd, X., Azizi, M., Baguet, J.-P., Bedel, J.-L., Benetos, A., Boivin, J.-M., Bricca, G., Chamontin, B., Denolle, T., Dupont, E., Fauvel, J.-P., Fayolle, P., Ghasarossian, C., Giral, P., Gury, C., Herpin, D., Jeunemaitre, X., Juilliere, Y., Kretz, S., Lacolley, P., Laurent, S., Lemaire, A., Lemogne, C., Lequeux, B., London, G., Mallion, J.-M., Mounier-Vehier, C., Nguyen, J.-P., Pernin, D., Pinto, E., Protogerou, A., Ribstein, J., Saillard, D., Sosner, P., Targowla Scandolo, N., Thuillez, C., Vaisse, B., Villeneuve, F., and Yannoutsos, A.

Published
2013
Full Text
View/download PDF

20. Effets vasculaires et rénaux des médicaments anti-angiogéniques: recommandations françaises pour la pratique: Société de néphrologie, Société française d’hypertension artérielle, Association pédagogique nationale des enseignants de thérapeutique et Fédération francophone de cancérologie digestive

Author

Halimi, J. -M., Azizi, M., Bobrie, G., Bouché, O., Deray, G., des Guetz, G., Lecomte, T., Levy, B., Mourad, J. -J., Nochy, D., Oudard, S., Rieu, P., and Sahali, D.

Published
2009
Full Text
View/download PDF

29. Évaluation de la morbi-mortalité à deux ans des patients traités pour une fibrillation auriculaire non valvulaire après une hospitalisation pour surdosage en anticoagulants

Author

Benainous, R., primary, Elourimi, G., additional, Abad, S., additional, Mazoyer, E., additional, Warzocha, U., additional, Baron, S., additional, Le Jeune, S., additional, Lopez-Sublet, M., additional, Giroux-Leprieur, B., additional, Larroche, C., additional, Mourad, J.-J., additional, and Dhôte, R., additional

Published
2018
Full Text
View/download PDF

31. Abdominal Aortic Calcifications Influences the Systemic and Renal Hemodynamic Response to Renal Denervation in the DENERHTN (Renal Denervation for Hypertension) Trial

Author

Courand, Pierre‐Yves, primary, Pereira, Helena, additional, Del Giudice, Costantino, additional, Gosse, Philippe, additional, Monge, Matthieu, additional, Bobrie, Guillaume, additional, Delsart, Pascal, additional, Mounier‐Vehier, Claire, additional, Lantelme, Pierre, additional, Denolle, Thierry, additional, Dourmap, Caroline, additional, Halimi, Jean Michel, additional, Girerd, Xavier, additional, Rossignol, Patrick, additional, Zannad, Faiez, additional, Ormezzano, Olivier, additional, Vaisse, Bernard, additional, Herpin, Daniel, additional, Ribstein, Jean, additional, Bouhanick, Beatrice, additional, Mourad, Jean‐Jacques, additional, Ferrari, Emile, additional, Chatellier, Gilles, additional, Sapoval, Marc, additional, Azarine, Arshid, additional, Azizi, Michel, additional, Amar, L., additional, Bobrie, G., additional, Lorthioir, A., additional, Monge, M., additional, Pagny, J.‐Y., additional, Plouin, P. F., additional, Sapoval, M., additional, Claisse, G., additional, Delsart, P., additional, Midulla, M., additional, Mounier‐Vehier, C., additional, Courand, P. Y., additional, Dauphin, R., additional, Fauvel, J. P., additional, Lantelme, P., additional, Rouvière, O., additional, Cremer, A., additional, Gosse, P., additional, Grenier, N., additional, Lebras, Y., additional, Trillaud, H., additional, Denolle, T., additional, Dourmap‐Collas, C., additional, Heautot, J. F., additional, Larralde, A., additional, Paillard, F., additional, Cluzel, P., additional, Girerd, X., additional, Rosenbaum, D., additional, Alison, D., additional, Halimi, J. M., additional, Claudon, M., additional, Popovic, B., additional, Rossignol, P., additional, Zannad, F., additional, Baguet, J. P., additional, Ormezzano, O., additional, Thony, F., additional, Bartoli, J. M., additional, Vaïsse, B., additional, Drouineau, J., additional, Herpin, D., additional, Sosner, P., additional, Tasu, J. P., additional, Velasco, S., additional, Ribstein, J., additional, Kovacsik, H., additional, Bouhanick, B., additional, Chamontin, B., additional, Rousseau, H., additional, Le Jeune, S., additional, Lopez‐Sublet, M., additional, Mourad, J. J., additional, Bellmann, L., additional, Esnault, V., additional, Ferrari, E., additional, Chatellier, G., additional, Durand‐Zaleski, I., additional, Beregi, J. P., additional, Lièvre, M., additional, and Persu, A., additional

Published
2017
Full Text
View/download PDF

35. [PP.08.06] IS THE DEVELOPMENT OF TELEMEDICINE IN HYPERTENSION A DIGITAL IMMIGRANT ISSUE ?

Author

Lopez-Sublet, M., primary, Baguet, J.-P., additional, Courand, P.-Y., additional, Bally, S., additional, Krummel, T., additional, Dimitrov, Y., additional, Brucker, M., additional, Regnier-Le-Coz, S., additional, Dourmap, C., additional, Mourad, J.-J., additional, Steichen, O., additional, Ott, J., additional, Barone, J., additional, Bogetto-Graham, L., additional, Rossignol, P., additional, Barber-Chamoux, N., additional, Le Jeune, S., additional, Agnoletti, D., additional, Baguet, S., additional, and Sosner, P., additional

Published
2016
Full Text
View/download PDF

36. [PP.10.08] PRESENCE OF AORTIC ABDOMINAL CALCIFICATIONS IN PATIENTS WITH RESISTANT HYPERTENSION AND BP RESPONSE IN THE RENAL DENERVATION FOR HYPERTENSION (DENERHTN) TRIAL

Author

Courand, P.-Y., primary, Pereira, H., additional, Gosse, P., additional, Bobrie, G., additional, Delsart, P., additional, Mounier-Vehier, C., additional, Lantelme, P., additional, Denolle, T., additional, Dourmap, C., additional, Halimi, J.–M., additional, Girerd, X., additional, Rossignol, P., additional, Baguet, J.-P., additional, Vaisse, B., additional, Herpin, D., additional, Ribstein, J., additional, Chamontin, B., additional, Mourad, J.-J., additional, Ferrari, E., additional, and Azizi, M., additional

Published
2016
Full Text
View/download PDF

37. [PP.09.02] ACCESSORY RENAL ARTERIES IN RESISTANT HYPERTENSION

Author

Le Jeune, S., primary, Radhouani, I., additional, Sosner, P., additional, Perez, L., additional, Barber-Chamoux, N., additional, Boudghene-Stambouli, F., additional, Lopez-Sublet, M., additional, Brucker, M., additional, Delsart, P., additional, Baguet, S., additional, Dourmap, C., additional, and Mourad, J.-J., additional

Published
2016
Full Text
View/download PDF

42. PP.39.19

Author

Levy, B., primary, Richard, A., additional, Zlatanova, I., additional, and Mourad, J.-J., additional

Published
2015
Full Text
View/download PDF

44. Vascular and renal effects of anti-angiogenic drugs: recommendations for French practice. (The Company of Nephrology, American Society of Hypertension, National Educational Association of Teachers of Therapeutics and Francophone Federation of Digestive Cancerology)

Author

Halimi, J. -M., Azizi, M., Bobrie, G., Bouche, O., Deray, G., Des Guetz, G., Lecomte, T., Levy, B., Mourad, J. -J., Nochy, D., Oudard, S., Rieu, P., Sahali, D., Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Génétique, immunothérapie, chimie et cancer (GICC), UMR 6239 CNRS [2008-2011] (GICC UMR 6239 CNRS), Université de Tours (UT)-Centre National de la Recherche Scientifique (CNRS), Hôpital Lariboisière, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Tours-Centre National de la Recherche Scientifique (CNRS), Cambefort, Jeanne, Hôpital Européen Georges Pompidou [APHP] ( HEGP ), CHU Pitié-Salpêtrière [APHP], Génétique, Immunothérapie, Chimie et Cancer ( GICC ), Université de Tours-Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Lariboisière-Université Paris Diderot - Paris 7 ( UPD7 ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Lariboisière-Université Paris Diderot - Paris 7 (UPD7), and Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)

Subjects
[SDV] Life Sciences [q-bio], Proteinuria, [SDV]Life Sciences [q-bio], Hypertension, Treatments, Vessels, Anti-angiogenic drugs, Safety, urologic and male genital diseases, Side effects, Kidney, VEGF, Cancer
Abstract

National audience; Angiogenesis inhibitor drugs (bevacizumab, sunitinib, sorafenib, etc.) are now widely used for treatment of cancers, including colorectal, advanced renal-cell and hepatocellular carcinomas, breast cancer). Vascular and renal side-effects of the drugs are not well known. Hypertension is one of the most common side effects. Incidence of hypertension may be different among angiogenis inhibitors, and seems dose-depend. Arterial pressure can usually be controlled with antihypertensive medications, and treatment with angiogenesis inhibitors can be continued in most cases; however, serious hypertension-induced side effects were reported included malignant hypertension, stroke and reversible posterior leucoencephalopathy. Renal damage is infrequently reported: usually reversible mild or moderate proteinuria and in some rare cases nephritic syndrome, acute renal dysfunction, proliferative or collapsing glomerulonephritis, interstitial nephritis and thrombotic microangiopathy. Prolongation of the QT interval, congestive heart failure and left ventricular dysfunction have been reported in patients using tinibs. In the present guidelines, we recommend: 1) before the 1st administration of angiogenesis inhibitors: giving acute i.v. or oral antihypertensive medications in a patient with arterial pressure must be avoided; postponing the administration because of hypertension is not recommended; 2) initial workup should include ambulatory measurement of arterial pressure ( by the general practitioner or by the patient using home blood pressure ( 3 times in the morning and in the evening during three consecutive days) with a validated (cf.: http://afssaps.sante.fr/) upper arm device. Using 24-hour ambulatory blood pressure measurement is optional; 3) urine dipstick ( and quantification is positive) and estimated glomerular filtration rate ( using abbreviated MDRD rather than Cockcroft-Gault formula) must be performed before treatment and regularly during follow-up; 4) therapeutic management must be done in accordance with national or international guidelines ( in France: http://www.hassante.fr/); 5) Optimal care is best achieved within a network of professionals including general practitioners, oncologists, cardiologists and nephrologists.

Published
2009

48. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: A meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients

Author

Vark, L.C. (Laura) van, Bertrand, M.E. (Michel), Akkerhuis, K.M. (Martijn), Brugts, J.J. (Jasper), Fox, K. (Kim), Mourad, J.-J. (Jean-Jacques), Boersma, H. (Eric), Vark, L.C. (Laura) van, Bertrand, M.E. (Michel), Akkerhuis, K.M. (Martijn), Brugts, J.J. (Jasper), Fox, K. (Kim), Mourad, J.-J. (Jean-Jacques), and Boersma, H. (Eric)

Abstract

AimsRenin-Angiotensin-Aldosterone system (RAAS) inhibitors are well established for the reduction in cardiovascular morbidity, but their impact on all-cause mortality in hypertensive patients is uncertain. Our objective was to analyse the effects of RAAS inhibitors as a class of drugs, as well as of angiotensin-converting enzyme (ACE) inhibitors and AT1 receptor blockers (ARBs) separately, on all-cause mortality. Methods and resultsWe performed a pooled analysis of 20 cardiovascular morbiditymortality trials. In each trial at least two-thirds of the patients had to be diagnosed with hypertension, according to the trial-specific definition, and randomized to treatment with an RAAS inhibitor or control treatment. The cohort included 158 998 patients (71 401 RAAS inhibitor; 87 597 control). The incidence of all-cause death was 20.9 and 23.3 per 1000 patient-years in patients randomized to RAAS inhibition and controls, respectively. Overall, RAAS inhibition was associated with a 5 reduction in all-cause mortality (HR: 0.95, 95 CI: 0.911.00, P = 0.032), and a 7 reduction in cardiovascular mortality (HR: 0.93, 95 CI: 0.880.99, P = 0.018). The observed treatment effect resulted entirely from the class of ACE inhibitors, which were associated with a significant 10 reduction in all-cause mortality (HR: 0.90, 95 CI: 0.840.97, P = 0.004), whereas no mortality reduction could be demonstrated with ARB treatment (HR: 0.99, 95 CI: 0.941.04, P = 0.683). This difference in treatment effect between ACE inhibitors and ARBs on all-cause mortality was statistically significant (P-value for heterogeneity 0.036). ConclusionIn patients with hypertension, treatment with an ACE inhibitor results in a significant further reduction in all-cause mortality. Because of the high prevalence of hypertension, the widespread use of ACE inhibitors may result in an important gain in lives saved.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results